Table 3.
Antibody levels after completion of primary series of COVID-19 vaccination and a booster dose.
| Study * | Antibody and Value Measured | Days Post Primary Series | Pre-Booster Titre (IQR) † | Days Post Booster | Post-Booster Titre (IQR) † | Fold Increase ‡ |
|---|---|---|---|---|---|---|
| Schmiedeberg et al. [22] | Anti-S1 antibody level (U/mL) | - | 19.5 (0.45–48) | 14 | 2500 (798–2500) | 128.21 |
| Schell et al. [23] | Anti-RBD antibody titre | 32 (29–34) | 31 (16–61) | 37 (32–47) | 68 (32–147) | 2.19 |
| Jyssum et al. [24] | Anti-RBD antibody titre (AU/mL) | 7–10 | 3 (2–18) | 21 | Rise: 0.96 (0.05–27.38) | - |
| Speer et al. [25] | Anti-S1 IgG index | 103 (72–126) | 0.1 (0.1–1.8) | 21 | 5.6 (0.5–150) | 56 |
| Speer et al. [25] | Neutralising surrogate antibodies | 103 (72–126) | 9 (0–35) | 21 | 56 (4–94) | 6.2 |
| Yang et al. [28] | Anti-S1 antibody (OD ratio) | 14 | 1.2 (0.2–5.2) | At least 7 | 3.3 (1.0–7.9) | 2.75 |
| Yang et al. [28] | ACE2 blocking (%) | 14 | 0.0 (0.0–10.2) | At least 7 | 9.0 (0.0–42.5) | NA |
| Madelon et al. [31] | Anti-RBD antibody titre (U/mL) | - | GMT: 3.5 | 30 | GMT: 57.9 | 16.5 |
| Dreyer-Alster et al. (Cladribine) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 686.3 | 0–3 months | GMT: 2345.6 | 3.42 |
| Dreyer-Alster et al. (Glatiramer acetate) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 581.9 | 0–3 months | GMT: 2530.1 | 4.35 |
| Dreyer-Alster et al. (Diroximelfumarate) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 335.7 | 0–3 months | GMT: 5830.4 | 17.37 |
| Dreyer-Alster et al. (Immunoglobulins) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 145.8 | 0–3 months | GMT: 5077.4 | 34.82 |
| Dreyer-Alster et al. (Natalizumab) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 286.6 | 0–3 months | GMT: 2161.4 | 7.54 |
| Dreyer-Alster et al. (Dimethyl fumarate) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 181.8 | 0–3 months | GMT: 2255.6 | 12.41 |
| Dreyer-Alster et al. (Teriflunomide) [32] | Anti-S1 antibody titre (BAU/mL) | At least 6 months | GMT: 373.7 | 0–3 months | GMT: 2331.2 | 6.24 |
| Mallory et al. [33] | Serum IgG against ancestral SARS-CoV-2 (EU) | 14 | 43905 | 28 | 204367 | 4.65 |
| Connolly et al. [34] | Anti-RBD antibody level (U/mL) | 77 | <0.4 (<0.4–222) | 30 (27–36) | 2500 (885–2500) | >6250 |
| Assawasaksakul et al. [35] | Anti-RBD antibody level (U/mL) | - | 83.3 (31.6–341.6) | 14 | 19,986 (15,079–59,735) | 239.93 |
* Includes data from all participants irrespective of serological status after primary series. † Median and interquartile ranges reported unless otherwise stated. ‡ Interquartile range unless otherwise stated. Abbreviations: RBD, receptor-binding domain; GMT, geometric mean titre.